Disease Sciences Announces Research Projects to Commence.

Business Editors/Health & Medical Writers

BOCA RATON, Fla.--(BUSINESS WIRE)--Jan. 14, 2002

Disease Sciences, Inc. (OTC BB: DSSC) announced today that its research Projects with Dr. Paul Brown for studies on the efficacy of incineration to inactivate scrapie infectivity and

the use of Multi-pulse high pressure to clean the food and plasma supplies of scrapie infectivity to commence. Scrapie is one member of the group of Transmissible Spongiform Encephalopathies ("TSE") diseases such as Bovine Spongiform ("BSE") in cattle (commonly known as "mad-cow disease"), Chronic Wasting Disease ("CWD") in wild deer and elk and Creutzfeldt-Jakob Disease ("CJD") in humans.

"Researchers believe using multiple high pressure pulsing should show a significant reduction in prion protein by immunological testing, and that it is generally agreed that the level of protein is paralleled by the level of infectivity," stated Dr. Brown.

Pressure testing will be performed this month, and bioassays will follow within the next few weeks. Bioassays of the already prepared incineration specimens are expected to begin in March. Approximately a year of observation following inoculation of the bioassay animals will be required before results will be known.

About Disease Sciences Inc.

Disease Sciences, Inc. is a developmental stage biopharmaceutical/clinical diagnostics Company. Its primary goal will be the development of drugs through its subsidiary, HealthSpan Sciences, Inc. HealthSpan Sciences, is developing small-molecule pharmaceutical products that fight age-related or degenerative diseases by attacking the underlying biochemical origins of degenerative processes. The Company's main focus is on life-enhancing pharmaceuticals that treat cardiovascular disease, cancer, and persistent infections. Also, the Company plans to use a broad array of technologies to detect, identify and quantify substances in blood or other bodily fluids and tissues. Its goal will be a Transmissible Spongiform Encephalopathy ("TSE") test, useful in the diagnosis of TSE diseases such as Bovine Spongiform Encephalopathy ("BSE") in cattle (commonly known as "mad-cow disease"), Scrapie in sheep, Chronic Wasting Disease ("CWD") in wild deer and elk and Creutzfeldt-Jakob Disease ("CJD") in humans. Test results are to be used in the diagnosis, detection, evaluation, monitoring and potential treatment of diseases and other medical conditions. The Company plans to derive its revenues from patent sub-licensing fees, drug development, royalties from pharmaceutical sales, appropriate milestone payments and research and development contracts. The Company, maintains a website at www.diseasesciences.com.

The foregoing press release contains forward-looking statements that can be identified by such terminology such as "expects", "potential", "will", "suggests", "may", or similar expression. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. In particular, management's expectations regarding future research development results could be affected by, among other things, uncertainties relating to clinical trials and product development; availability of future financing; unexpected regulatory delays or government regulation generally; the Company's ability to obtain or maintain patent and other proprietary intellectual property protection; and competition in general. Forward-looking statements speak only as to the date they are made. The Company does not undertake to update forward-looking statements to reflect circumstances or events that occur after the date of the forward-looking statements are made.